Tesamorelin + Ipamorelin Blend (5 mg Vial) Dosage Protocol
Tesamorelin + Ipamorelin combines a long-acting GHRH analog with a clean GHRP for amplified pulsatile GH release plus visceral-fat-targeting effects. 1:1 blend ratio (5 mg + 5 mg in 10 mg vial).
⚡ Quickstart Highlights
Dosing & Reconstitution Guide
Route: Subcutaneous | Frequency: Once daily (evening preferred) | Half-life: Mixed
Standard Approach (3 mL = 1.67 mg/mL)
Reconstituting with 3 mL bacteriostatic water produces a concentration of 1.67 mg/mL. Volume per dose changes with concentration; mg dose itself does not change between vial sizes.
| Phase / Protocol | Dose | U-100 Units | Volume | Doses per vial |
|---|---|---|---|---|
| Weeks 1–2 (titration) | 375 mcg | 22.5 units | 0.22 mL | 13 doses |
| Weeks 3–4 | 750 mcg | 45.0 units | 0.45 mL | 6 doses |
| Weeks 5–6 | 1.5 mg | 90.0 units | 0.90 mL | 3 doses |
| Weeks 7–10 | 2.25 mg | 135 units | 1.35 mL | 2 doses |
| Weeks 11–16 (target) | 3 mg | 180.0 units | 1.80 mL | 1 doses |
Reconstitution Steps
- Wipe the vial stopper and BAC water vial with alcohol; let dry.
- Draw 3 mL of bacteriostatic water into a sterile syringe.
- Inject slowly down the inside glass wall of the peptide vial. Do not aim at the powder.
- Gently swirl until fully dissolved. Do not shake.
- Label with reconstitution date. Refrigerate at 2–8°C; use within 2 days.
Supplies Needed
Estimates for an 8-week and 12-week cycle at 1.5 mg per dose, once daily (evening preferred) (7 doses/week).
| Item | 8-Week Cycle | 12-Week Cycle |
|---|---|---|
| Tesamorelin + Ipamorelin Blend (5 mg) vials | 19 vials | 28 vials |
| Insulin syringes (U-100) | 56 | 84 |
| Bacteriostatic water (10 mL) | 6 × 10 mL | 9 × 10 mL |
| Alcohol swabs | 1 × 100-pack | 2 × 100-pack |
Protocol Overview
This blend pairs tesamorelin's visceral-fat-targeting GHRH effect with ipamorelin's clean GHRP amplification. Most useful when both visceral fat reduction AND general GH-axis stimulation are protocol goals.
Dosing Protocol
Daily titration (subcutaneous, evening preferred):
- Weeks 1–2 (titration): 375 mcg/day.
- Weeks 3–4: 750 mcg/day.
- Weeks 5–6: 1.5 mg/day.
- Weeks 7–10: 2.25 mg/day.
- Weeks 11–16 (target): 3.0 mg/day. Most-cited blended dose.
Cycle: 12–24 weeks for visceral-fat-focused protocols, then 4-week break.
Storage Instructions
| State | Temperature | Duration |
|---|---|---|
| Lyophilized | −20°C (−4°F) | Up to 24 months, dry & dark |
| Reconstituted | 2–8°C (35–46°F) | Up to 2 days, protect from light |
Important Notes
How This Works
Tesamorelin (GHRH analog) stimulates pituitary GH release; ipamorelin (selective GHRP) amplifies the GHRH-driven pulse via the ghrelin receptor. The blend provides tesamorelin's visceral-fat-reducing properties alongside enhanced GH amplitude.
Potential Benefits & Side Effects
Potential Benefits
- Combined visceral-fat reduction + amplified GH pulse.
- Pre-bed dosing aligns with natural overnight pulse.
Side Effect Profile
- Combined profile of components.
- Injection-site reactions.
- Joint stiffness from GHRH.
Lifestyle Factors
- Pre-bed dosing.
- Avoid eating 1–2h after injection.
- Resistance training amplifies anabolic effects.
Injection Technique
- Subcutaneous, rotate sites daily.